Genomma Lab Internacional SAB de CV (GNMLF) Price & Analysis

Q: What was Genomma Lab Internacional SAB de CV Class B’s price range in the past 12 months?

Genomma Lab Internacional SAB de CV Class B lowest stock price was $0.78 and its highest was $1.31 in the past 12 months.

Q: What is Genomma Lab Internacional SAB de CV Class B’s market cap?

Genomma Lab Internacional SAB de CV Class B’s market cap is $847.78M.

Q: When is Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date?

Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date is Jul 22, 2026 which is tomorrow.

Q: How were Genomma Lab Internacional SAB de CV Class B’s earnings last quarter?

Genomma Lab Internacional SAB de CV Class B released its earnings results on Apr 23, 2026. The company reported $0.028 earnings per share for the quarter, beating the consensus estimate of $0.026 by $0.002.

Q: Is Genomma Lab Internacional SAB de CV Class B overvalued?

According to Wall Street analysts Genomma Lab Internacional SAB de CV Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Genomma Lab Internacional SAB de CV Class B pay dividends?

Genomma Lab Internacional SAB de CV Class B pays a Quarterly dividend of $0.011 which represents an annual dividend yield of 5.38%. See more information on Genomma Lab Internacional SAB de CV Class B dividends here

Q: What is Genomma Lab Internacional SAB de CV Class B’s EPS estimate?

Genomma Lab Internacional SAB de CV Class B’s EPS estimate is 0.03.

Q: How many shares outstanding does Genomma Lab Internacional SAB de CV Class B have?

Genomma Lab Internacional SAB de CV Class B has 1,000,000,000 shares outstanding.

Q: What happened to Genomma Lab Internacional SAB de CV Class B’s price movement after its last earnings report?

Genomma Lab Internacional SAB de CV Class B reported an EPS of $0.028 in its last earnings report, beating expectations of $0.026. Following the earnings report the stock price went down -7.014%.

Q: Which hedge fund is a major shareholder of Genomma Lab Internacional SAB de CV Class B?

Currently, no hedge funds are holding shares in GNMLF

16 Followers

GNMLF Stock Chart & Stats

$1.08

>-$0.01(-0.39%)

At close: Nov 22 4:00 PM EST

$1.08

>-$0.01(-0.39%)

Day’s Range― - ―

52-Week Range$0.78 - $1.31

Previous CloseN/A

Volume11.81K

Average Volume (3M)836.00

Market Cap

$847.78M

Enterprise Value$23.20K

Total Cash (Recent Filing)$2.38B

Total Debt (Recent Filing)$5.06B

Price to Earnings (P/E)9.0

Beta0.67

Next Earnings

Jul 22, 2026

EPS Estimate

0.03

Next Dividend Ex-DateN/A

Dividend Yield5.38%

Share Statistics

EPS (TTM)0.60

Shares Outstanding1,000,000,000

10 Day Avg. Volume2,510

30 Day Avg. Volume836

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda<0.01

Forecast

1Y Price Target

$0.91

Price Target Upside-15.55% Downside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Genomma Lab Internacional SAB de CV News

Genomma Lab initiated with a Hold at Jefferies

Jefferies initiated coverage of Genomma Lab (GNMLF) with a Hold rating and MXN 16 price target The firm...

2d ago

GNMLF Earnings this Week: How Will it Perform?

Genomma Lab Internacional SAB de CV Class B (GNMLF) is scheduled to report 2nd quarter earnings on 07/22/2026,...

2d ago

GNMLF Upcoming Earnings Report: What to Expect?

Genomma Lab Internacional SAB de CV Class B (GNMLF) is scheduled to report 1st quarter earnings on 04/22/2026,...

3M ago

GNMLF Earnings this Week: How Will it Perform?

Genomma Lab Internacional SAB de CV Class B (GNMLF) is scheduled to report 4th quarter earnings on 02/25/2026,...

5M ago

Genomma Lab Faces Challenges with Strategic Optimism

Genomma Lab Internacional SAB de CV Class B (($MX:LABB)) has held its Q3 earnings call. Read on for...

9M ago

Genomma Lab Faces Challenges Amidst Economic Pressures

Genomma Lab Internacional SAB de CV Class B ( ($GNMLF) ) has released its Q3 earnings. Here is...

9M ago

Genomma Lab Internacional SAB de CV Class B (GNMLF) Q3 Earnings Cheat Sheet

Genomma Lab Internacional SAB de CV Class B (GNMLF) is scheduled to report 3rd quarter earnings on 10/22/2025,...

9M ago

Genomma Lab Reports Mixed Q2 2025 Results

Genomma Lab Internacional SAB de CV Class B ( ($GNMLF) ) has released its Q2 earnings. Here is...

12M ago

GNMLF Upcoming Earnings Report: What to Expect?

Genomma Lab Internacional SAB de CV Class B (GNMLF) is scheduled to report 2nd quarter earnings on 07/23/2025,...

1y ago

Genomma Lab Reports Strong Q1 2025 Performance

Genomma Lab Internacional SAB de CV Class B ( ($GNMLF) ) has released its Q1 earnings. Here is...

1y ago

Genomma Lab Internacional SAB de CV (GNMLF) Reveals Q1 Dividend: Here’s the Essential Information

Genomma Lab Internacional SAB de CV (Other OTC: GNMLF) has declared, under its dividend policy, a quarterly cash...

1y ago

Genomma Lab upgraded to Buy from Neutral at BTG Pactual

BTG Pactual upgraded Genomma Lab to Buy from Neutral with a MXN 28 price target. The firm sees...

2y ago

Genomma Lab downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Antonio Hernandez downgraded Genomma Lab to Equal Weight from Overweight with a price target of MXN...

3y ago

Genomma Lab downgraded to Neutral from Buy at UBS

UBS analyst Rodrigo Alcantara downgraded Genomma Lab to Neutral from Buy with a price target of MXN 18,...

3y ago

GNMLF FAQ

What was Genomma Lab Internacional SAB de CV Class B’s price range in the past 12 months?

Genomma Lab Internacional SAB de CV Class B lowest stock price was $0.78 and its highest was $1.31 in the past 12 months.

What is Genomma Lab Internacional SAB de CV Class B’s market cap?

Genomma Lab Internacional SAB de CV Class B’s market cap is $847.78M.

When is Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date?

Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date is Jul 22, 2026 which is tomorrow.

How were Genomma Lab Internacional SAB de CV Class B’s earnings last quarter?

Genomma Lab Internacional SAB de CV Class B released its earnings results on Apr 23, 2026. The company reported $0.028 earnings per share for the quarter, beating the consensus estimate of $0.026 by $0.002.

Is Genomma Lab Internacional SAB de CV Class B overvalued?

According to Wall Street analysts Genomma Lab Internacional SAB de CV Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genomma Lab Internacional SAB de CV Class B pay dividends?

Genomma Lab Internacional SAB de CV Class B pays a Quarterly dividend of $0.011 which represents an annual dividend yield of 5.38%. See more information on Genomma Lab Internacional SAB de CV Class B dividends here

What is Genomma Lab Internacional SAB de CV Class B’s EPS estimate?

Genomma Lab Internacional SAB de CV Class B’s EPS estimate is 0.03.

How many shares outstanding does Genomma Lab Internacional SAB de CV Class B have?

Genomma Lab Internacional SAB de CV Class B has 1,000,000,000 shares outstanding.

What happened to Genomma Lab Internacional SAB de CV Class B’s price movement after its last earnings report?

Genomma Lab Internacional SAB de CV Class B reported an EPS of $0.028 in its last earnings report, beating expectations of $0.026. Following the earnings report the stock price went down -7.014%.

Which hedge fund is a major shareholder of Genomma Lab Internacional SAB de CV Class B?

Currently, no hedge funds are holding shares in GNMLF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genomma Lab Internacional SAB de CV Class B

Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies, specializes in the formulation, promotion, and worldwide distribution of non-prescription pharmaceuticals and personal hygiene products. The firm's extensive product range covers areas such as skincare, general health and wellness, haircare, pain management, cold and flu remedies, gastrointestinal treatments, sexual health, antiperspirant deodorants, hand sanitizers, rehydration drinks, and shaving essentials. It also provides analgesics, antifungal solutions, and hemorrhoid treatments. These items are sold under numerous recognized brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Incorporated in 1996, Genomma Lab Internacional, S.A.B. de C.V. is headquartered in Mexico City, Mexico.

Genomma Lab Internacional SAB de CV (GNMLF) Earnings & Revenues

Historic Earnings Reports

GNMLF Stock 12 Month Forecast

Average Price Target

$0.91

▼(-15.55% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.912096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.912096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.912096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.887,0.8889304615384616,0.8908609230769231,0.8927913846153847,0.8947218461538462,0.8966523076923077,0.8985827692307693,0.9005132307692307,0.9024436923076923,0.9043741538461538,0.9063046153846154,0.9082350769230769,0.9101655384615385,{"y":0.912096,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.887,0.8889304615384616,0.8908609230769231,0.8927913846153847,0.8947218461538462,0.8966523076923077,0.8985827692307693,0.9005132307692307,0.9024436923076923,0.9043741538461538,0.9063046153846154,0.9082350769230769,0.9101655384615385,{"y":0.912096,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.887,0.8889304615384616,0.8908609230769231,0.8927913846153847,0.8947218461538462,0.8966523076923077,0.8985827692307693,0.9005132307692307,0.9024436923076923,0.9043741538461538,0.9063046153846154,0.9082350769230769,0.9101655384615385,{"y":0.912096,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.07,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.147,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.018,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.994,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.975,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.968,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.976,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.898,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.89,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.887,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >